Chris Grygon is Executive Director, R&D External Liaison in the Innovation Unit at Boehringer Ingelheim Pharmaceuticals, Inc. In this role, she is responsible for global visibility and communications strategy for the Discovery Research, Business Development and Licensing, and other innovation functions within BI’s human pharma business. Dr. Grygon has previously held senior level positions in Business Development and Licensing as Head of BI’s internal CDx Center for Partnering and Knowledge, which had oversight for Companion Diagnostics partnering strategy in support of Boehringer’s drug development pipeline and as Acting Head, Global Licensing – Oncology, where she was responsible for strategy and evaluation around external alliances for Boehringer’s oncology portfolio. Prior to that, she was Head, Technology Investments for North America, responsible for sourcing external innovation to support Boehringer’s Research and Development functions. She has held positions as Executive Director of Biologics and Biomolecular Sciences, where she established and led a technology infrastructure group in support of the discovery of new protein therapeutics in collaboration with Boehringer’s R&D group in North America and manufacturing groups in Europe. Her team was also responsible for enabling specialized technology platforms to facilitate innovative drug discovery research for BI worldwide. She has pharmaceuticals expertise in both small molecule and protein biotherapeutic drug discovery.
Dr. Grygon obtained her B.S. degree in chemistry from the University of Delaware and her M.A. and Ph.D. degrees in chemistry from Princeton University. She is an inventor on five patents and an author on over twenty three peer-reviewed scientific publications. She was a 2008 finalist for the Connecticut Technology Council Women of Innovation, Research Innovation and Leadership Award. She is a dedicated mentor in helping women achieve leadership roles (Women Unlimited LEAD), especially in STEM fields.